Anavex Life Sciences Corp (AVXL)

[anders2211]

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson's disease (PD) will continue to grow, and this is expected to double by 2040. TThe average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

https://www.mordorintelligence.com/industry-reports/parkinsons-disease-drugs-market

If Anavex is able to proof efficiency for Parkinson would the target market then be: USD 2,500 x 1.2 million for the US + same for EU + same for rest of the world = 9 billion per year? In other words would it be fair to say that the MC for Anavex could become at least 9 billion after efficiency has been proven? Only for Parkinson this excludes Alz and RETT and other CNS...